Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.21.5 extracted from

  • Stangier, J.; Clemens, A.
    Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor (2009), Clin. Appl. Thromb. Hemost., 15, 9S-16S.
    View publication on PubMed

Inhibitors

Inhibitors Comment Organism Structure
dabigatran BIBR 953, potent competitive and reversible inhibitor of thrombin, inhibiting both thrombin activity and generation, dabigatran displays highly selective, rapid, and reversible binding to thrombin8 and potently inhibits platelet aggregation with a concentration that produces 50% inhibition similar to the Ki of thrombin Homo sapiens

Natural Substrates/ Products (Substrates)

Natural Substrates Organism Comment (Nat. Sub.) Natural Products Comment (Nat. Pro.) Rev. Reac.
fibrinogen + H2O Homo sapiens
-
fibrin + fibrinopeptide A + fibrinopeptide B
-
?

Organism

Organism UniProt Comment Textmining
Homo sapiens
-
-
-

Source Tissue

Source Tissue Comment Organism Textmining
blood plasma
-
Homo sapiens
-

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
fibrinogen + H2O
-
Homo sapiens fibrin + fibrinopeptide A + fibrinopeptide B
-
?

Ki Value [mM]

Ki Value [mM] Ki Value maximum [mM] Inhibitor Comment Organism Structure
0.0000045
-
dabigatran
-
Homo sapiens